Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
In this exploratory study, the human immunodeficiency virus (HIV) protease inhibitor atazanavir was detected in seminal plasma in 15 out of 15 HIV-infected men taking an atazanavir-containing regimen. However, this penetration was limited and variable, and the median seminal/blood plasma ratio was only 0.1.
van Leeuwen
E
E
Academic Medical Centre, Obstetrics and Gynecology, H4-205, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands. e.vanleeuwen@amc.uva.nl
Ter Heine
R
R
van der Veen
F
F
Repping
S
S
Beijnen
J H
JH
Prins
J M
JM
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D000069446:Atazanavir Sulfate; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D012367:RNA, Viral / Q000097:blood; D012661:Semen / Q000378:metabolism*; D013997:Time Factors; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D012367:RNA, Viral; D000069446:Atazanavir Sulfate